Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 463 (TSX: $LABS.TO)
(CSE: $PLUS.C) (CSE: $THC.C)
Delta, Kelowna, BC, September 3, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/090320-StocksToWatch.mp3
Read this news in
full at https://www.investorideas.com/news/2020/cannabis-potcasts/09031LABS-PLUS-THC.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
Reformulary Group, an
expert-led healthcare company that helps Canadians make sense of medicine
(prescription drugs and medical cannabis, announced the
launch of its Cannabis Standard™ Index. The Index uniformly categorizes medical
cannabis products based on objective data, allowing Canadians and the medical
community to find accurate, detailed information and to reliably search and
compare products.
"We want to help patients, and
their doctors make sense of medical cannabis, so we worked with a group of
experts to develop a standardized classification system as is the norm with
prescription and over-the-counter drugs, but designed explicitly for
cannabinoid-based medicine," said Helen Stevenson, founder and CEO of
Reformulary Group. "The Cannabis Standard Index makes it possible for
patients and healthcare professionals to search and compare cannabis products
and to determine which are similar or interchangeable."
The Index is an educational tool
that allows medical cannabis patients and their doctors to assess and compare
products made by different Licensed Producers (LPs) using objective data such
as composition, format and form rather than strain name. As there are no
industry standards for the naming of strains, some producers may apply strain
names to products with different concentrations of cannabinoids. By indexing
products using objective data, including the presence of major (THC, CBD) and
minor cannabinoids (THCA, CBDA, CBG, CBC, CBN) where the information is
available, the Index can help guide reliable prescribing and therapeutic substitutions.
So, when a medical cannabis patient seeks a change in product type or when a
patient's usual LP runs out of stock, they can find an effective alternative.
A national study conducted by RIWI
Corp., a global trend-tracking and prediction technology firm, in summer 2019
revealed that two-thirds of medical cannabis patients were interested in a
rating system that categorizes cannabis into product types and helps consumers
compare products.
[New study underscores importance of
medical cannabis rating system: https://reformulary.com/news/new-study-underscores-importance-of-medical-cannabis-rating-system]
The Index is the latest addition to
Cannabis Standard, an ecosystem of expert recommendations, patient-powered
tools, and independent information to help Canadians and healthcare
professionals make smarter, more informed decisions about medical cannabis.
"The addition of the Index to
the Cannabis Standard ecosystem empowers patients and healthcare practitioners
to access and evaluate medical cannabis with the same level of sophistication
as with prescription drugs," said Dr. Alan Bell, family physician and
Assistant Professor in the Department of Family and Community Medicine at the
University of Toronto.
"Rather than relying on a
product strain name, or user-generated reviews, we now have a system to help
categorize and differentiate medical cannabis using data relevant for doctors
and patients," he added."When medicine makes sense, we all
benefit," said Ms. Stevenson, who is the former Assistant Deputy Minister
of Health in Ontario. In this role, she ran Ontario's $4 billion drug program,
overseeing the Ontario Drug Benefit Formulary. The Cannabis Index borrows from
some of the same principles as Reformulary's award-winning DrugFinder™ tool.
DrugFinder is broadly offered by Canadian employers to their plan members, and
provides patients and plan members with evidence-based information about their
medication, empowering them to make informed choices.
The Cannabis Standard Index is free
and open source. Reformulary Group endeavors to include products from as many
licensed producers as possible. It does not sell cannabis, receives no
commissions and does not benefit from the sale of medical cannabis.
MediPharm
Labs Corp.
(TSX:
LABS) (OTCQX:
MEDIF)
today announced that its wholly owned subsidiary MediPharm
Labs Inc. will supply premium, formulated cannabis oil to Cann Farm Peru S.A.C., a Lima-based producer and distributor
serving Peruvian and other markets in Latin America.
This is MediPharm Labs first such
agreement in Latin America and the most recent example of the Company’s
international growth strategy in action. As part of this strategy, the Company
has expanded its addressable medical, wellness and adult-use markets to parts
of Asia Pacific, Europe and now Latin America.
MediPharm Labs is creating footholds
in medical, wellness and adult-use markets around the world and in Latin
American countries. With a combined population of approximately 580 million -
and beginning with its fifth largest country Peru – Latin America factors
highly in the Company’s business plan. As an early mover among Latin American
countries, Peru has created a legal framework for producing, importing and
selling cannabis for medical use. As a result, Peru’s market is advancing
rapidly and offers the potential to register varied formats of cannabis based
products. Using a range of pricing, consumption and patient datasets, the LATAM
Cannabis Report™ by Prohibition Partners(1) forecasts that the LATAM
market is expected to exceed US$12 billion by 2028, offering “serious growth
potential to global cannabis companies.”
“Peru is one of the top medical
cannabis markets in the world and Cann Farm is one of very few cannabis companies
which hold both a DroguerÃa licence and cannabis importation licence which
makes this agreement of outstanding strategic value to MediPharm Labs,” said
Pat McCutcheon, CEO, MediPharm Labs. “As we pursue our global ambitions, it is
vital for us to partner with companies of Cann Farm’s calibre who know their
local markets intimately, have a real appreciation for the needs of patients,
an ongoing commitment to scientific advancement and a sound plan for regional
expansion. We expect great things from this collaboration.”
Under the one-year renewable
agreement, MediPharm Labs Inc. will provide a variety of cannabis concentrate
formats, with optionality for patient ready formulated products. The products
will be distributed to patients through pharmacies in Peru. Cann Farm will in
turn obtain all Peruvian registrations, authorizations and approvals required
for importation. In the future, Cann Farm may look to MediPharm Labs for
further support in commercialization activities. MediPharm Labs anticipates delivery
to begin in Q4 2020, pending regulatory approval by applicable health
authorities.
“Cann Farm was created from our deep
commitment to patients, who demand reliable, consistent high quality, and
proven product integrity; therefore we choose our partners very carefully,”
said Andres Vazquez Vargas, Executive President, Cann Farm Peru. “What
impresses us most about MediPharm Labs is their focus on medical markets and
their commitment to our production standards, as is seen with their GMP
certification, which is the gold standard in pharma production. It’s rare to
see GMP certification in the cannabis supply chain because it’s a complex and
rigorous process to earn the qualification. This tells us all we need to know
about their ability to meet our needs on not only a continuous, but consistent
basis.”
Plus
Products Inc. (CSE:
PLUS) (OTCQX:
PLPRF)
today announced the launch of its new PLUS SLEEP brand into the
California adult-use market.
Highlights
●
4 key ingredients to promote a well-rounded
night of sleep: THC, CBN, CBD, and just a touch of melatonin.
●
All-natural colors and flavors, with only
0.7g of sugar and 5 calories per gummy.
●
2 formulations to offer multiple potential
solutions to a wide range of consumers: Sleep
Cloudberry, with 5mg of THC, 1mg of CBN, and 1mg of CBD, along with CBNRelief Lychee, with 1mg of THC, 2mg
of CBN, and 3mg of CBD.
PLUS’s new SLEEP gummies are scientifically formulated with a precise blend of
cannabinoids and melatonin intended to help consumers fall asleep quickly and
enjoy a full, restful night’s sleep.
Recent research on the interaction
between cannabis, the endocannabinoid system, and the body’s natural circadian
rhythm¹ drove PLUS’s formulations of the two new SLEEP products. “Each cannabinoid was selected for how it promotes
better sleep, but together they have the potential to be greater than the sum
of their parts. This is often referred to as the entourage effect.2
We also included a physiologic dose of melatonin to support our bodies’
circadian rhythm, so these gummies actually work in concert with our natural
systems,” stated Dr. Ari Mackler, Chief Scientific Officer.
“We’re excited to help the 71% of
cannabis sleep aid users who are not satisfied with their current remedies3,”
stated Jake Heimark, CEO and Co-Founder. “Almost 50 million people in the US
suffer from insomnia.4 It’s no surprise we hear all the time that one of the top
things people look for when they walk into a licensed retailer is something to
help them sleep.”
THC
BioMed Intl Ltd. (CSE:THC) announced that it
has shipped its "Ready to Drink" Cannabis Beverage Shot, THC KISS, to
the Ontario Cannabis Store. OCS is the only legal online retailer of
recreational cannabis in Ontario.
THC Kiss is also available for
purchase in B.C. and Saskatchewan. THC BioMed is in discussion with other
provinces to widen its distribution.
THC KISS is a breakthrough Cannabis
Beverage Shot that promises to offer a different experience compared to edibles
and beverages currently available in either the grey or legal cannabis markets.
THC Kiss aims to be an alternative
to smoking cannabis and was developed by THC BioMed using proprietary
extraction methods invented by THC BioMed.
"We are proud to bring
Canadians a true alternative to smoking cannabis," commented John Miller,
president and CEO.
"We continue to receive very
positive feedback from consumers. We have received many requests that indicate
a high demand for our current products and those in development. THC BioMed
continues to deliver a wide array of cannabis products to cater for all classes
of cannabis consumers. In addition, all of our products are developed,
manufactured and packaged by THC BioMed itself," said Mr. Miller.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and followers.
Contact management and IR of each company directly regarding specific
questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news,
articles, podcasts and
stock directory
No comments:
Post a Comment